Earlier in the pandemic, coronavirus products boosted the revenue and the stock prices of companies selling those products. But these days, those products actually have done just the opposite, dragging down performance.

It's important to keep in mind, though, that some of these players offer (or are set to offer) revenue growth well beyond the coronavirus portfolio. So right now, with their shares trading at bargain prices, they've become no-brainer buys.

Which companies am I talking about? Coronavirus testing giant Abbott Laboratories (NYSE: ABT) and vaccine leaders Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE). Let's take a closer look at each of these stocks as possible buys right now.

Continue reading

Source Fool.com